Nikolaus Krall - Exscientia Executive Medicine
| EXAIDelisted Stock | USD 4.84 0.00 0.00% |
Executive
Nikolaus Krall is Executive Medicine of Exscientia Ltd ADR
| Phone | 44 18 6581 8941 |
| Web | https://www.exscientia.ai |
Exscientia Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4643) %, meaning that it created substantial loss on money invested by shareholders. Exscientia's management efficiency ratios could be used to measure how well Exscientia manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Verender Badial | Zura Bio Limited | 52 | |
| Paul MD | Sana Biotechnology | N/A | |
| Mahesh Padval | Relay Therapeutics | N/A | |
| Alexander Azoy | Unity Biotechnology | 48 | |
| Nathan Guz | Unity Biotechnology | N/A | |
| Chad Cowan | Century Therapeutics | N/A | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| Przemyslaw Sapieha | Unity Biotechnology | N/A | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
| Wayne CPA | Atea Pharmaceuticals | 55 | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Douglas CPA | Century Therapeutics | N/A | |
| Peter Rahmer | Relay Therapeutics | N/A | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Yuko JD | Sana Biotechnology | N/A | |
| Jayanthi Wolf | Atea Pharmaceuticals | N/A | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Nancy Agrawal | Atea Pharmaceuticals | N/A | |
| Juliet BA | Kymera Therapeutics | N/A | |
| Deanne Randolph | PDS Biotechnology Corp | N/A | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 |
Exscientia ADR Leadership Team
Elected by the shareholders, the Exscientia's board of directors comprises two types of representatives: Exscientia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exscientia. The board's role is to monitor Exscientia's management team and ensure that shareholders' interests are well served. Exscientia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exscientia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Overington, Chief Officer | ||
| Eileen JenningsBrown, Chief Officer | ||
| Ben AshwellFryer, VP Fin | ||
| Parker Moss, Executive Development | ||
| Ben Taylor, Chief CFO | ||
| CBE DPHIL, CEO Founder | ||
| Nikolaus Krall, Executive Medicine | ||
| Dan Ireland, Executive Secretary | ||
| Heather Togwell, Operations Mang | ||
| Caroline Rowland, Chief Officer | ||
| Chris Thomas, VP People | ||
| Garry Pairaudeau, Chief Officer | ||
| MarieLouise MD, Interim Lead | ||
| FRSE DPHIL, CEO Founder | ||
| David Hallett, Interim Officer | ||
| Michael MD, Chief Officer | ||
| Margo Mosley, VP Operations | ||
| Richard Law, Chief Officer | ||
| Sara Sherman, Vice Relations |
Exscientia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exscientia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (10.66) % | ||||
| Current Valuation | 346.92 M | ||||
| Shares Outstanding | 130.82 M | ||||
| Shares Owned By Insiders | 25.90 % | ||||
| Shares Owned By Institutions | 20.80 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Book | 1.95 X | ||||
| Price To Sales | 37.10 X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exscientia Ltd ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Exscientia Stock
If you are still planning to invest in Exscientia ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Exscientia's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |